Phase 1b study of vactosertib in combination with nal-IRI plus 5FU/LV in patients with metastatic pancreatic ductal adenocarcinoma who have failed first-line gemcitabine/nab-paclitaxel

被引：3
|
作者：
Park, Joon Oh
Kim, Seung Tae
Hong, Jung Yong
Kim, Seong-Jin
Park, Young Suk
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea
[2] GILO Fdn, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.TPS632
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS632
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel, and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC)
    Dai, Guang-Hai
    Jia, Ru
    Si, Haiyan
    Wang, Zhi-Kuan
    Deng, Guo-Chao
    Zhang, Nan
    Liu, Fang-Fang
    Shi, Yue
    Zhang, Yao-Yue
    Jia, Yu-Shan
    Zhang, Bei
    Tong, Shuang
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Phase III study (daNIS-2) of the antieTGF-β monoclonal antibody NIS793 with nab-paclitaxel/gemcitabine vs nab-paclitaxel/gemcitabine alone in patients with first-line metastatic pancreatic ductal adenocarcinoma
    O'Reilly, E.
    Golan, T.
    Ikeda, M.
    Milella, M.
    Taieb, J.
    Wainberg, Z.
    Wang, L.
    Gyambibi, N.
    Lopez, E.
    Xu, K.
    Macarulla, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S254 - S254
  • [23] RAMP 205: A phase 1b/2a study of gemcitabine, nab-paclitaxel, avutometinib, and defactinib in untreated metastatic pancreatic ductal adenocarcinoma
    Lim, Kian-Haut
    Hidalgo, Manuel
    O'Hara, Mark H.
    Spencer, Kristen R.
    Garrido-Laguna, Ignacio
    DeNardo, David G.
    Bhambhani, Vijeta
    Patrick, Gloria
    Cheng, Yaofeng
    Coma, Silvia
    Pachter, Jonathan A.
    Denis, Louis J.
    CANCER RESEARCH, 2024, 84 (02)
  • [24] Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment
    Pretta, Andrea
    Ziranu, Pina
    Giampieri, Riccardo
    Donisi, Clelia
    Cimbro, Erika
    Spanu, Dario
    Lai, Eleonora
    Pecci, Federica
    Balconi, Francesca
    Lupi, Alessio
    Pozzari, Marta
    Persano, Mara
    Murgia, Sara
    Pusceddu, Valeria
    Puzzoni, Marco
    Berardi, Rossana
    Scartozzi, Mario
    DIGESTIVE AND LIVER DISEASE, 2023, 55 (05) : 655 - 660
  • [25] Efficacy of SBP-101, a polyamine metabolic inhibitor, administered in combination with gemcitabine and nab-paclitaxel, as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma
    Singhal, Nimit
    Sigal, Darren
    Tebbutt, Niall C.
    Hezel, Aram F.
    Nagrial, Adnan
    Lumba, Sumit
    George, Thomas J.
    Smith, Sheri Lynn
    Gagnon, Suzanne
    Cullen, Michael T.
    Walker, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [26] Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma, a retrospective cohort
    Wu, Hongyang
    Huang, Nana
    Zhao, Chenchen
    Hu, Xueyang
    Da, Liangshan
    Huang, Wei
    Shen, Yuanyuan
    Xiong, Fuxing
    Zhang, Congjun
    ANNALS OF TRANSLATIONAL MEDICINE, 2022, 10 (06)
  • [27] A phase Ib study evaluating olaratumab in combination with nab-paclitaxel and gemcitabine in first-line treatment of metastatic pancreatic cancer.
    Pelzer, Uwe
    Bendell, Johanna C.
    Womack, Mark S.
    Bahary, Nathan
    Macarulla, Teresa
    Borazanci, Erkut Hasan
    Levy, Donna Elise
    Mo, Gary
    Ramage, Samuel Cowan
    Garrido-Laguna, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [28] Sequential therapy of metastatic pancreatic ductal adenocarcinoma (PDAC) after failure of gemcitabine plus nab-paclitaxel with either 5-FU/folinic acid (5FU/LV) plus irinotecan (FOLFIRI) followed by 5FU/LV plus oxaliplatin (OFF) or the reverse sequence: The PANTHEON trial (AIO PAK 0116)
    Modest, D. P.
    Heinemann, V.
    Schuett, P.
    Angermeier, S.
    Haberkorn, M.
    Waidmann, O.
    Graeven, U.
    Wille, K.
    Kunzmann, V.
    Henze, L.
    Constantin, C.
    De Wit, M.
    Denzlinger, C.
    Kurreck, A.
    Alig, A. H. S.
    Stahler, A.
    Pelzer, U.
    Stintzing, S.
    Oettle, H.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1139 - S1139
  • [29] Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma
    Li, Zhiwei
    Fan, Xiaona
    Jiang, Dan
    Li, Qingwei
    Liu, Chao
    Wang, Dan
    Li, Na
    Li, Hengzhen
    Chen, Zhuo
    Tang, Hongzhen
    Lou, Changjie
    Xu, Haitao
    Zhan, Chao
    Dong, Yuandi
    Ma, Zhigang
    Wang, Guangyu
    Zhang, Chunhui
    Lu, Haibo
    Zheng, Tongsen
    Zhang, Yanqiao
    ONCOLOGIST, 2024, 29 (11):
  • [30] Liposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: Further subgroup analyses of the pivotal NAPOLI-1 study
    Chen, L-T.
    Macarulla Mercade, T.
    Lee, K-H.
    Lakatos, G.
    Wang-Gillam, A.
    Mirakhur, B.
    de Jong, F.
    ANNALS OF ONCOLOGY, 2018, 29
12345